The Peter Attia Drive: Early LDL Control, APOE4, and Alzheimer’s Risk

0:00Let's talk about prevention and timing. Because in this episode of the Peter Atia Drive, Peter sits down with Michael Davidson, a cardiologist at the University of Chicago whose entire career has been shaped by personal tragedy. His father died of a heart attack at just 47 years old. And that loss pushed Davidson into lipid research in clinical trials. But what really stands out here is his core argument. Atherosclerosis should be treated early, not after the damage is already done. He actually says something pretty striking. If you keep your LDL below 80 milligrams per desolator throughout your lifetime, you don't get heart disease. That's a bold statement. But the logic makes sense. It's easier to stop plaque from forming than to reverse it later. Though I imagine convincing a healthy 30 year old to start therapy is no easy task. Exactly. Davidson admits that's the challenge.

1:00But he's making the case for what he calls primordial prevention. And he doesn't hold back when criticizing how LDL gets treated. He points out that we don't wait for a stroke or heart failure to treat hypertension, yet LDL gets treated like a stepchild. Right. And he emphasizes using tools like family history, genetic testing, coronary calcium scores, plaque imaging, LP little A and CRP to sharpen risk assessment long before symptoms appear. But then the conversation shifts to something really interesting, C-E-P-P inhibition. This is where the discussion gets technical, but fascinating. Davidson walks through the entire history. Torse atrepib, Delse atrepib, Avassa atrepib, Anissa atrepib. The field originally thought these drugs would work by raising HDL, but that wasn't the real story. What they eventually realized was that no one had been considering these drugs for LDL

2:00lowering. Anissa atrepib ultimately proved that the clinical benefit came from absolute LDL reduction, not HDL raising. Which brings us to Obisatrepib, the C-E-T-P inhibitor now in development at New Amsterdam Pharma. Davidson describes large phase 2 and phase 3 programs, with names like Brooklyn, Broadway, Pandem, and the Outcome Trial prevail. The drug appears to lower LDL substantially, reduce LPA, and possibly lower diabetes risk. And importantly, it's being studied as a companion to statins, not a replacement, but here's where things take an unexpected turn. The second half shifts to Alzheimer's disease. Davidson makes this really compelling connection. He says Alzheimer's is a disease of middle age that presents in old age. He links APOE4, C-E-T-P loss of function, HDL biology, and brain cholesterol handling.

3:01There's genomic data from Centenarian studies, especially the Bronx aging study, where C-E-T-P loss of function seem to blunt APOE4 associated risk. And that leads into biomarker science. P-T-217, P-T-181, GFP, Neural Filament Light, Amaloid Ratios, Seribor Spinal Fluid Signals, the common thread running through everything is orally intervention. Davidson's ultimate argument is that both cardiovascular disease and Alzheimer's become much harder to stop once symptoms appear. The future of prevention depends on earlier testing, smarter trials, combination therapy, and reaching patients before irreversible damage sets in. It's really about rethinking when treatment should begin.